Dramatic increase in SHP2 binding activity of Helicobacter pylori Western CagA by EPIYA-C duplication: Its implications in gastric carcinogenesis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Nagase, Lisa ^a,b   Hayashi, Takeru ^a,b   Senda, Toshiya ^b,c   Hatakeyama, Masanori ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c INSTITUTE OF MATERIALS STRUCTURE SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CAGA PROTEIN, HELICOBACTER PYLORI; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE SHP 2;

BINDING SITE; CARCINOGENESIS; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; STOMACH; STOMACH TUMOR;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BINDING SITES; CARCINOGENESIS; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; STOMACH; STOMACH NEOPLASMS;

EID: 84945958804     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15749     Document Type: Article

References (40)

1. Blaser, M. J. et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 55, 2111-2115 (1995).
2. Parsonnet, J., Friedman, G. D., Orentreich, N. and Vogelman, H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 40, 297-301 (1997).
3. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136, E359-E386 (2015).
4. Covacci, A. and Rappuoli, R. Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J Exp Med 191, 587-592 (2000).
5. Hayashi, T. et al. Tertiary structure-function analysis reveals the pathogenic signaling potentiation mechanism of Helicobacter pylori oncogenic effector CagA. Cell host microbe 12, 20-33 (2012).
6. Muller, A. Multistep activation of the Helicobacter pylori effector CagA. The Journal of clinical investigation 122, 1192-1195, (2012).
7. Segal, E. D., Cha, J., Lo, J., Falkow, S. and Tompkins, L. S. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci USA 96, 14559-14564 (1999).
8. Hatakeyama, M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 4, 688-694 (2004).
9. Higashi, H. et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci USA 99, 14428-14433 (2002).
10. Karlsson, A., Ryberg, A., Dehnoei, M. N., Borch, K. and Monstein, H. J. Association between cagA and vacA genotypes and pathogenesis in a Helicobacter pylori infected population from South-eastern Sweden. BMC Microbiol 12, 129 (2012).
11. Xia, Y., Yamaoka, Y., Zhu, Q., Matha, I. and Gao, X. A comprehensive sequence and disease correlation analyses for the C-terminal region of CagA protein of Helicobacter pylori. PLoS One 4, e7736 (2009).
12. Higashi, H. et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 295, 683-686, (2002).
13. Chan, G., Kalaitzidis, D. and Neel, B. G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 27, 179-192 (2008).
14. Ohnishi, N. et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA 105, 1003-1008 (2008).
15. Basso, D. et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 135, 91-99 (2008).
16. Batista, S. A. et al. Higher number of Helicobacter pylori CagA EPIYA C phosphorylation sites increases the risk of gastric cancer, but not duodenal ulcer. BMC Microbiol 11, 61 (2011).
17. Beltran-Anaya, F. et al. The EPIYA-ABCC motif pattern in CagA of Helicobacter pylori is associated with peptic ulcer and gastric cancer in Mexican population. BMC Gastroenterol 14, 2 (2014).
18. Ferreira, R. M., Machado, J. C., Leite, M., Carneiro, F. and Figueiredo, C. The number of Helicobacter pylori CagA EPIYA C tyrosine phosphorylation motifs influences the pattern of gastritis and the development of gastric carcinoma. Histopathology 60, 992-998 (2012).
19. Gonzalez, I. et al. High prevalence of virulence-associated genotypes in Helicobacter pylori clinical isolates in the Region del Maule, Chile. Scand J Infect Dis 43, 652-655 (2011).
20. Sicinschi, L. A. et al. CagA C-terminal variations in Helicobacter pylori strains from Colombian patients with gastric precancerous lesions. Clin Microbiol Infect 16, 369-378 (2010).
21. Aceto, N. et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 18, 529-537 (2012).
22. Sausgruber, N. et al. Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases. Oncogene 34, 2272-2278 (2015).
23. Wang, H. C., Chiang, W. F., Huang, H. H., Shen, Y. Y. and Chiang, H. C. Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis. BMC Cancer 14, 442 (2014).
24. Yang, X., Dutta, U. and Shaw, L. M. SHP2 mediates the localized activation of Fyn downstream of the α6β4 integrin to promote carcinoma invasion. Mol Cell Biol 30, 5306-5317 (2010).
25. Kinoshita, E., Kinoshita-Kikuta, E., Takiyama, K. and Koike, T. Phosphate-binding tag, a new tool to visualize phosphorylated proteins. Mol Cell Proteomics 5, 749-757 (2006).
26. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J. and Shoelson, S. E. Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441-450 (1998).
27. Nagase, L., Murata-Kamiya, N. and Hatakeyama, M. Potentiation of Helicobacter pylori CagA protein virulence through homodimerization. J Biol Chem 286, 33622-33631 (2011).
28. Saadat, I. et al. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature 447, 330-333 (2007).
29. Higashi, H. et al. Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation. J Biol Chem 279, 17205-17216 (2004).
30. Hanahan, D. and Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
31. Acosta, N., Quiroga, A., Delgado, P., Bravo, M. M. and Jaramillo, C. Helicobacter pylori CagA protein polymorphisms and their lack of association with pathogenesis. World J Gastroenterol 16, 3936-3943 (2010).
32. Shokrzadeh, L. et al. Analysis of 3'-end variable region of the cagA gene in Helicobacter pylori isolated from Iranian population. J Gastroenterol Hepatol 25, 172-177 (2010).
33. Hayashi, T., Morohashi, H. and Hatakeyama, M. Bacterial EPIYA effectors-where do they come from? What are they? Where are they going? Cell Microbiol 15, 377-385 (2013).
34. Nam, Y. H. et al. CagA phosphorylation-dependent MMP-9 expression in gastric epithelial cells. Helicobacter 16, 276-283 (2011).
35. Lu, P., Takai, K., Weaver, V. M. and Werb, Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 3, a005058 (2011).
36. Pickup, M. W., Mouw, J. K. and Weaver, V. M. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 15, 1243-1253 (2014).
37. Blum, E. S., Schwendeman, A. R. and Shaham, S. PolyQ disease: misfiring of a developmental cell death program? Trends Cell Biol 23, 168-174 (2013).
38. Li, B., Qing, L., Yan, J. and Kong, Q. Instability of the octarepeat region of the human prion protein gene. PLoS One 6, e26635 (2011).
39. Naito, M. et al. Influence of EPIYA-repeat polymorphism on the phosphorylation-dependent biological activity of Helicobacter pylori CagA. Gastroenterology 130, 1181-1190 (2006).
40. Murata-Kamiya, N., Kikuchi, K., Hayashi, T., Higashi, H. and Hatakeyama, M. Helicobacter pylori exploits host membrane phosphatidylserine for delivery, localization, and pathophysiological action of the CagA oncoprotein. Cell Host Microbe 7, 399-411 (2010).